Synoviorthesis with 32P-colloidal chromic phosphate in rheumatoid arthritis--clinical, histopathologic and arthrographic changes.
Synoviorthesis was performed in 217 joints from 111 patients suffering from different stages of rheumatoid arthritis (RA). 32P-colloidal chromic phosphate was employed, with an average dose from 6 mCi for large joints (knees) to 0.3 mCi for small peripheral joints such as average dose from 6 mCi for large joints (knees) to 0.3 mCi for small peripheral joints such as the MCP or PIP joints. Satisfactory clinical results were observed in 84% of the cases and no significant side effects resulted after a follow-up period from 1 to 10 years. Striking effects after treatment were observed through histopathological studies (light and electron microscopy) and the use of contrast arthrography. We concluded that radioactive synovectomy with 32P-chromate is a very useful method for the local treatment of RA.
D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D002857:Chromium / Q000627:therapeutic use*; D017608:Chromium Compounds; D003102:Colloids; D005260:Female; D006801:Humans; D008297:Male; D008854:Microscopy, Electron; D010043:Outcome and Process Assessment, Health Care; D010710:Phosphates / Q000627:therapeutic use*; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use*; D011859:Radiography
D017608:Chromium Compounds; D003102:Colloids; D010710:Phosphates; D010761:Phosphorus Radioisotopes; D002857:Chromium; C509369:chromic phosphate